The development of non invasive biomarkers of disease has become a major focus of
interest in nonalcoholic fatty liver disease (NAFLD). The large prevalence of the disease and …

The spectrum of nonalcoholic fatty liver disease (NAFLD) ranges from asymptomatic
steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis. Hepatic steatosis occurs …

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver
enzymes in both adults and children. NAFLD has a histologic spectrum ranging from simple …

Nonalcoholic fatty liver disease (NAFLD), defined as abnormal accumulation (> 5%) of
hepatic triglyceride without excess alcohol intake, is the most common form of chronic liver …

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of elevated liver
function tests results, after the commonly investigated causes have been excluded, and …

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease,
affecting approximately 25% of the general population worldwide, and is forecasted to …

Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent worldwide and becoming
a major cause of liver disease-related morbidity and mortality. The presence of liver fibrosis …

Hepatic steatosis without specific causes (eg, viral infection, alcohol abuse, etc.) is called
non-alcoholic fatty liver disease (NAFLD), which ranges from non-alcoholic fatty liver (NAFL) …

Despite affecting around one‐fourth of the general population worldwide, non‐alcoholic fatty
liver disease (NAFLD) remains a largely under‐recognized disease in primary healthcare …

Abstract Background and Aim Non‐alcoholic steatohepatitis (NASH) is the progressive form
of non‐alcoholic fatty liver disease (NAFLD). A liver biopsy is considered the “gold standard” …